Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
NeuroEndocrine Tumours
Interventions
DRUG

lanreotide acetate

Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days

Trial Locations (14)

Unknown

Basingstoke & North Hampshire Hospital, Basingstoke

Queen Elizabeth Hospital, Birmingham

University Hospital Wales, Cardiff

Beatson West of Scotland Cancer Centre, Glasgow

St James's University Hospital, Leeds

University Hospital Aintree, Liverpool

Hammersmith Hospital, London

King's College Hospital, London

Royal Free Hospital, London

Maidstone Hospital, Maidstone

The Christie Hospital, Manchester

Norfolk & Norwich Hospital, Norwich

Royal Hallamshire Hospital, Sheffield

Southampton University Hospital, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY